Media Archive | Revolution Medicines

Scientific Presentations Archive

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017

The information included below was provided in connection with a presentation or publication on the date indicated and is qualified as such. Revolution Medicines disclaims any duty to update these materials.

Publication / Presentation

April 18, 2023

Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1

Publication / Presentation

April 17, 2023

Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma

Publication / Presentation

April 17, 2023

RMC-9805, a First-in-Class, Mutant-Selective, Covalent and Orally Bioavailable KRASG12D(ON) Inhibitor, Promotes Cancer-Associated Neoantigen Recognition and Synergizes with Immunotherapy in Preclinical Models

Publication / Presentation

April 17, 2023

RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Publication / Presentation

April 16, 2023

Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression

Publication / Presentation

April 16, 2023

RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Publication / Presentation

April 16, 2023

Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor

Publication / Presentation

December 19, 2022

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Publication / Presentation

October 27, 2022

Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors

Publication / Presentation

June 7, 2022

The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial Clinical Findings from A Single Agent Phase 1/1b Study

Publication / Presentation

April 12, 2022

Direct Targeting of KRAS-G12X Mutant Cancers with RMC-6236, a First-in-Class, RAS-Selective, Orally Bioavailable, Tri-complex RAS-MULTI(ON) Inhibitor

Publication / Presentation

April 12, 2022

RMC-6291, a Next-Generation Tri-Complex KRAS-G12C(ON) Inhibitor, Outperforms KRAS-G12C(OFF) Inhibitors in Preclinical Models of KRAS-G12C Cancers

Publication / Presentation

April 12, 2022

RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound Anti-Tumor Activity in KRAS-G12D Mutant Tumor Models

Publication / Presentation

April 12, 2022

A First-In-Class Tri-complex KRAS-G13C(ON) Inhibitor Validates Therapeutic Targeting of KRAS-G13C and Drives Tumor Regressions in Preclinical Models

Publication / Presentation

April 12, 2022

Translating Frontier Oncology Targets to Outsmart RAS-Addicted Cancers

Publication / Presentation

April 10, 2022

Potential for Next Generation RAS Inhibitors in Adult and Pediatric Cancers

Publication / Presentation

April 9, 2022

Targeting KRAS-G12C and Beyond

Publication / Presentation

February 5, 2022

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy

Publication / Presentation

October 9, 2021

Discovery and Development of RAS(ON) Inhibitors Beyond KRAS-G12C

Publication / Presentation

September 22, 2021

Combination Strategies to Defeat RAS-Addicted Cancers

Publication / Presentation

September 22, 2021

Targeting KRAS-G12C(ON) and Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors

Publication / Presentation

June 24, 2021

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Publication / Presentation

April 12, 2021

Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1 that suppresses 4EBP1 phosphorylation, for the treatment of mTORC1-activated tumors including RAS pathway escape

Publication / Presentation

April 10, 2021

Modulation of Innate and Adaptive Immunity in Blood and Tumor of Patients Receiving the SHP2 Inhibitor RMC-4630

Publication / Presentation

April 10, 2021

A Bi-Steric mTORC1 Inhibitor That Selectively Reactivates 4EBP1 and Induces Regression of MYC-Driven Hepatocellular Carcinoma

Publication / Presentation

April 10, 2021

Bi-steric mTORC1-selective inhibitors demonstrate improved potency and efficacy in tumors with mTORC1 hyperactivation

Publication / Presentation

April 10, 2021

Discovery of a potent, selective and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction

Publication / Presentation

April 10, 2021

A Next Generation Tri-Complex KRASG12C(ON) Inhibitor Directly Targets the Active, GTP-Bound State of Mutant RAS and may Overcome Resistance to KRASG12C(OFF) Inhibition

Publication / Presentation

April 10, 2021

Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Publication / Presentation

April 10, 2021

First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Publication / Presentation

April 10, 2021

Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study

Publication / Presentation

April 6, 2021

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation

Publication / Presentation

February 25, 2021

Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations

Publication / Presentation

October 24, 2020

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

Publication / Presentation

September 29, 2020

Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity

Publication / Presentation

September 16, 2020

Approaches to Inhibiting RAS Driven Tumors Beyond KRAS-G12C

Publication / Presentation

June 22, 2020

SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway

Publication / Presentation

June 22, 2020

Dual inhibition of SHP2 and CDK4/6 leads to immunological memory and immune-mediated anti-tumor activity in a mouse syngeneic model of breast cancer

Publication / Presentation

June 22, 2020

Positioning a selective, bi-steric inhibitor of mTORC1 as a combination partner in RAS-driven cancers

Publication / Presentation

June 22, 2020

Discovery and development of allosteric inhibitors of SHP2

Publication / Presentation

April 29, 2020

Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment

Publication / Presentation

February 26, 2020

Strategies to Inhibit RAS-Driven Cancers

Publication / Presentation

January 12, 2020

The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.

Publication / Presentation

January 12, 2020

Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC

Publication / Presentation

January 11, 2020

The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.

Publication / Presentation

November 20, 2019

Translating Frontier Oncology Targets To Outsmart Cancer Using Multiple Allosteric Approaches

Publication / Presentation

October 29, 2019

Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo

Publication / Presentation

October 28, 2019

Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo

Publication / Presentation

October 28, 2019

4EBP3 mRNA as a Biomarker of Therapeutic Response to Treatment with mTORC1 Inhibitors

Publication / Presentation

September 19, 2019

Translating Frontier Oncology Targets to Outsmart Cancer

Publication / Presentation

September 9, 2019

Discovery of Small Molecule Inhibitors of the Oncogenic, GTP-Bound (ON) Form of KRASG12C and KRASG13C

Publication / Presentation

September 9, 2019

Industry Leading RAS Drug Discovery Engine

Publication / Presentation

June 24, 2019

Inhibition of the Oncogenic, GTP-Bound Form of KRASG12C by Second Generation, Tri-Complex Inhibitors Overcomes RTK-Mediated Escape Mechanisms

Publication / Presentation

April 3, 2019

Allosteric inhibition of SHP2 suppresses CSF-1R signaling and selectively reduces viability of M2 tumor associated macrophages contributing to anti-tumor immunity

Publication / Presentation

April 2, 2019

Discovery of Small Molecule Inhibitors of Oncogenic Mutants of RAS

Publication / Presentation

April 1, 2019

Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling

Publication / Presentation

March 27, 2019

Shp1 Loss Drives Robust Anti-Tumor Immunity and Enhances Macrophage Effector Function

Publication / Presentation

March 26, 2019

Shp1 Loss Drives Robust Anti-Tumor Immunity and Enhances Macrophage Effector Function

Publication / Presentation

December 11, 2018

Development of Inhibitors of the Activated Form of KRAS G12C

Publication / Presentation

December 10, 2018

Biophysical and biochemical characterization of KRAS G12C inhibition through a novel modality

Publication / Presentation

December 1, 2018

4EBP1 Reactivation by Potent and Selective Bi-steric Inhibitors of mTORC1

Publication / Presentation

December 1, 2018

4EBP1 Reactivation by Potent and Selective Bi-steric Inhibitors of mTORC1

Publication / Presentation

November 13, 2018

Development of Inhibitors of the Activated Form of KRAS G12C

Publication / Presentation

September 30, 2018

Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms

Publication / Presentation

August 15, 2018

Combination Strategies to Enhance the Efficacy of SHP2 Inhibition

Publication / Presentation

August 13, 2018

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Publication / Presentation

July 19, 2018

Allosteric Inhibition of SHP2 Variants Containing Cancer-Associated Activating Mutations

Publication / Presentation

July 16, 2018

Functional characterization of SHP2-mediated RAS-MAPK pathway inhibition in cancer cells bearing oncogenic mutations dependent upon nucleotide cycling of RAS

Publication / Presentation

April 17, 2018

Discovery of an allosteric inhibitor of SHP2, RMC-4550

Publication / Presentation

April 17, 2018

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF

Publication / Presentation

April 17, 2018

Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations

Publication / Presentation

March 20, 2018

RMC-4550: An Allosteric Inhibitor Optimized for in Vivo Studies of SHP2

Publication / Presentation

September 14, 2017

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

New research revealed an unexpected dependence of some cancer-causing forms of proteins in the RAS-MAP kinase pathway on the normal biochemical actions of SHP2. These functions can be disrupted by small molecule inhibitors of SHP2 designed by…